ArticleCancer2020
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
Article in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Differences in prostate cancer treatment receipt and timeliness of treatment between African American/Black and White Iowans.Cancer causes & control : CCC · 2025Article
- Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.Cancer medicine · 2025Article
- Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.Circulation. Arrhythmia and electrophysiology · 2025Observational
- Variation in content discussed by specialty in consultations for clinically localized prostate cancer.Urologic oncology · 2024Article
- Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.JAMA network open · 2023Article
- Complications after Prostate Cancer Treatment: Pathophysiology and Repair of Post-Radiation Urethral Stricture Disease.Journal of clinical medicine · 2023Review
- Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse.iScience · 2022Article
- Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams.Targeted oncology · 2022Review
- Tackling Health Care Disparities: How to Build a Sarcoidosis Center.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Review
- Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.The Prostate · 2021Article
- Multidisciplinary clinics in prostate cancer.Oncotarget · 2021Article
- Influence of Geography on Prostate Cancer Treatment.International journal of radiation oncology, biology, physics · 2021Article
- A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer.World journal of urology · 2021Article
- Current Opinion Regarding Multidisciplinary Cancer Clinic Utilization for the Management of Prostate Cancer.Journal of clinical imaging science · 2021Article
- A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.BMC cancer · 2020Article
- The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.European urology · 2020Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors.
Funding
Abstract
backgroundThe purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic compared with nationwide trends.
methodsIn total, 4451 men with prostate cancer who presented at the MultiD clinic from 2004 to 2016 were analyzed. To assess nationwide trends, the authors analyzed 392,710 men with prostate cancer who were diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoint was treatment choice as a function of pretreatment demographics.
resultsUnivariate analyses revealed similar treatment trends in the MultiD and SEER cohorts. The use of procedural forms of definitive therapy decreased with age, including brachytherapy and prostatectomy (all P < .05). Later year of diagnosis/clinic visit was associated with decreased use of definitive treatments, whereas higher risk grouping was associated with increased use (all P < .001). Patients with low-risk disease treated at the MultiD clinic were more likely to receive nondefinitive therapy than patients in SEER, whereas the opposite trend was observed for patients with high-risk disease, with a substantial portion of high-risk patients in SEER not receiving definitive therapy. In the MultiD clinic, African American men with intermediate-risk and high-risk disease were more likely to receive definitive therapy than white men, but for SEER the opposite was true.
conclusionsPresentation at a MultiD clinic facilitates the appropriate disposition of patients with low-risk disease to nondefinitive strategies of patients with high-risk disease to definitive treatment, and it may obviate the influence of race.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.